OIS: Ophthalmology Innovation & Investment
Keith D. Ignotz, president and CEO of OcuMedic Inc., answers Three Critical Questions about how OcuMedic is looking to upend the $16 billion eye drop delivery market in ophthalmology.
The patented technology was developed by Mark Byrne, Ph.D., Distinguished Professor of Chemical and Biomedical Engineering & Founding Head of the Biomedical Engineering Department/Founding Dean Health Engineering and Science at Rowan University. Dr. Byrne serves as Co-founder of OcuMedic and Chief Technical Officer of the company. The technology rests on 10 issued patents, and a recent Freedom to Operate (FTO) opinion. Efficacy has been proven in animal models.
The technology is based on a novel therapeutic contact lens, made from the most widely used lens material, silicone hydrogel (SiHy), capable of controlled release of first line ophthalmic agents. The platform technology is tested for a use with anti-inflammatory and antibiotic agents, as well as 10 other drugs. It is also an ideal platform for treatment of dry eye especially episodic flairs.
Ocumedic aims for the clinic with drug-eluting, clear corneal bandage
By Stacy Lawrence, Staff Writer
Ophthalmic drugs and devices have proven a strong source of revenue growth as an aging, increasingly obese population aims to prevent eyesight deterioration.
ILSE White Paper Profiles New Jersey’s Innovators and Pipeline of Early-Stage Life Science Companies
UNION, N.J. — Institute for Life Science Entrepreneurship (ILSE) at Kean University has released “Profiles in Innovation,” the second in a series of white papers examining the state of innovation in New Jersey.READ PRESS RELEASE
Biomedical Engineering part of international vision research project
The Henry M. Rowan College of Engineering at Rowan University is part of an international team working to preserve the vision of patients with some of the leading causes of blindness. Dr. Mark Byrne, founding department…VIEW THE ARTICLE
New Contact Lens Technology to Deliver Drugs Directly to Eye; Improve Healing for Millions after Surgery and Lasik
Therapeutics soft lens designed to deliver pain and anti-infection drugs more evenly – replacing messy, less effective drops
The soft contact lenses, developed by biomedical researchers at Rowan University, are imprinted with anti-inflammatory or anti-biotic drugs that are deliver evenly over time potentially improving recovery time and reducing post-operative complications.
Approximately six million Americans undergo some type of eye surgery every year – four million cataract and one million post-corneal abrasion surgeries and 800,000 Lasik procedures.
All patients require post-operative care which includes eye drops which can wash out quickly, can be hard to administer or deliver a low concentration of medication all of which can aggravate post-operative complications. Approximately three million Americans suffer from Glaucoma, worldwide more than 60 million people are affected. Dry eyes affect about five million people in the U.S. and approximately 40 million worldwide.